EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Imlunestrant (Primary) ; Abemaciclib; Exemestane; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMBER-3
- Sponsors Eli Lilly and Company
- 03 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 30 Nov 2022 Planned number of patients changed from 800 to 860.